Dialog Box

Skin Health Institute

Clinical Trials Now Recruiting

These study descriptions are intended for potential study participants. Study descriptions for clinicians can be found here.  

You can also find us on Facebook: Follow our Clinical Trials page to keep up with all our currently recruiting trials, interesting patient stories, and more.

If you would like to learn more about any of the studies currently being conducted at the Skin Health Institute, please contact the nominated study coordinator.

If you have any general questions regarding the clinical trials conducted at the Institute, please feel free to contact the Clinical Trials Department at [email protected] or by phone at (03) 9623 9439. 

RESEARCH STUDY FOR ATOPIC DERMATITIS (24 WEEKS)

Adults within the age range of 18 and 75 with atopic dermatitis (AD) for at least 6 months, may qualify to receive investigational oral medication (active study drug) or placebo. 

To be eligible for the study, participants must have mild to severe AD on 5% or more of their body surface area (not limited to only hands and/or feet and/or scalp). Participants must agree to use a bland emollient (cream, gel, or ointment) twice daily throughout the trial. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Individuals will be asked to visit the study centre about 8 times over a period of approximately 24 weeks from screening to safety follow-up.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Irina Danilovich
t: 9623 9448
e: [email protected]

RESEARCH STUDY FOR ATOPIC DERMATITIS (22 WEEKS)

Adults aged 18 years or older with moderate to severe atopic dermatitis, may qualify to receive investigational oral medication (active study drug) or placebo. 

To be eligible, participants must have a diagnosis of chronic atopic dermatitis (AD), with a history of AD for 1 year or more.  AD must cover 5% or more body surface area.  Recent documented history (within 6 months) of inadequate response to topical AD treatments or for whom topical AD treatments are otherwise medically inadvisable, is also required.  Eligible participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 13 times over a period of about 22 weeks.

For more information, please contact: 

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Natasha Harrison
t: 9623 9482
e: [email protected]

ATOPIC DERMATITIS RESEARCH TRIAL (68 WEEKS)

Adults within the age range of 18 and 75 with atopic dermatitis (AD) for 1 year or longer, may qualify to receive investigational medication (active study drug) or placebo, via injection. 

To be eligible for the study, participants must have moderate to severe atopic dermatitis (AD) involving 10% or more body surface area. Individuals must have a documented history, within 6 months prior to Baseline, of either inadequate response or unable to use topical treatments. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Individuals will be asked to visit the study centre about 21 times and have 10 phone visits, over a period of approximately 68 weeks. 

For more information, please contact: 

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Irina Danilovich
t: 9623 9448
e: [email protected]

ATOPIC DERMATITIS CLINICAL STUDY (33 WEEKS)

Adults with a clinical diagnosis of chronic atopic dermatitis (AD) that has been present for at least 1 year, may qualify to receive investigational medication (active study drug) or placebo via subcutaneous injection. 

To be eligible, participants must have moderate to severe AD, with disease that affects ≥ 10% body surface area.  A history of inadequate response to, intolerance to or contraindication to a stable (≥ 1 month) regimen of topical corticosteroids or calcineurin inhibitors as treatment for AD within 3 months before the screening visit, is also required.  Eligible participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.

Study participation will last approximately 33 weeks and involve up to 16 visits to the study centre.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallet
t: 9623 9406
e: [email protected]

RESEARCH STUDY FOR NAIL AND BODY PSORIASIS (76 WEEKS)

Adults aged 18 years or older with moderate to severe nail and body psoriasis, may qualify to receive investigational medication (active study drug) or placebo, via subcutaneous injection. 

To be eligible, participants must have chronic, moderate to severe plaque-type psoriasis for at least 6 months. Psoriatic involvement of 10% or more body surface area (BSA) is required in addition to nail involvement/psoriasis. Participants must be considered candidates for systemic therapy, meaning psoriasis is inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Individuals will be asked to visit the study centre about 15 times over a period of about 76 weeks. 

For more information, please contact:

Principal Investigator

A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Irina Danilovich
t: 9623 9448
e: [email protected]

RESEARCH STUDY FOR PSORIATIC ARTHRITIS (66 WEEKS)

Adults who are at least 18 years of age with a diagnosis of psoriatic arthritis (PsA) for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo. 

To be eligible, participants must have active psoriatic arthritis with at least 3 swollen joints and 3 tender joints. Having active plaque psoriasis, with at least 1 psoriatic plaque of ≥2 cm diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis, is also required. Looking for individuals with an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as the presence of active PsA despite previous treatment with one prior anti-TNF alpha agent. 

Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Individuals will be asked to visit the study centre about 16 times over a period of about 66 weeks. 

For more information, please contact: 

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallet
t: 9623 9406
e: [email protected]

PSORIATIC ARTHRITIS AXIAL DISEASE RESEARCH STUDY (66 WEEKS)

Adults who are 18 years of age or older with a diagnosis of psoriatic arthritis (PsA) for at least 6 months, may qualify to receive investigational medication (active study drug) or placebo. 

To be eligible, participants must be bio-naïve (no prior biologic therapy received), and have active psoriatic arthritis axial disease with at least 3 swollen joints and 3 tender joints. Having active plaque psoriasis, with at least 1 psoriatic plaque of ≥2 cm diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis, is also required. Further eligibility criteria will be evaluated by the study site prior to participant enrolment into the study. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. 

Individuals will be asked to visit the study centre about 16 times over a period of approximately 66 weeks. 

For more information, please contact: 

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallet
t: 9623 9406
e: [email protected]


CHRONIC URTICARIA RESEARCH STUDY (42 WEEKS)

Adults who are 18-75 years of age with a diagnosis of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) for at least 3 months, may qualify to receive investigational medication (active study drug) or a comparator medication. 

To be eligible, participants must have the presence of itch and wheals (red, raised areas of skin) for 8 consecutive weeks or more at any time prior to study enrollment, despite current use of H1 antihistamine treatment during this time period. Individuals must have been on an approved dose of an H1 antihistamine for chronic urticaria for 3 consecutive days or more immediately prior to the start of screening. Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Individuals will be asked to visit the study centre about 13 times over a period of about 42 weeks.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Natasha Harrison
t: 9623 9482
e: [email protected]

HEALTHY VOLUNTEER BLOOD DONATION RESEARCH STUDY

Healthy volunteers aged 18 years or older, may qualify to donate up to 40mls of blood (equivalent to 3 tablespoons). The purpose of this research is to establish new bioassays (tests) that will support research and development of novel (new) biological therapies designed to target cancer, inflammatory, cardiovascular and Bleeding disorders (e.g. haemophilia).

To be eligible, participants must be 18 years or older and believe themselves to be HIV and Hepatitis B & C negative. Qualified participants may be asked to donate blood at regular intervals. Visits will take place at Skin Health Institute with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Approved by the Victorian Minister for Health under section 40 of the Human Tissue Act 1982.

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Ferial Ismail
t: 9623 9464
e: [email protected]

Study Coordinator
Desire Green
t: 9623 9439
e: [email protected]

Melanoma surveillance photography (MSP)

The IMAGE Study (Melanoma surveillance photography to improve early detection of melanoma) tests whether an advanced medical imaging technology called Melanoma Surveillance Photography (MSP), in addition to usual care, helps to improve outcomes compared to usual care alone.

This study is currently recruiting patients with a diagnosis of melanoma within the last 6 months (186 days). Your doctor will be discussing the IMAGE study with you because you have recently been diagnosed with your first melanoma and you may be eligible to participate - if other criteria are also met.

If you are:

  • Aged 18 years or older at date of diagnosis of your first melanoma.
  • Able to provide consent, complete questionnaires, and attend a local study site for MSP.
  • Able to be referred for total body photography (you will need to undress to underwear and stand for imaging)
  • Have “some” or “many” moles; and
  • Currently living in Australia and have no plans to move overseas within the next 3 years.

you may be eligible to participate in the IMAGE study.

There are certain types of melanomas that will mean you are not eligible, even if all criteria above have been met. Your doctor will discuss whether they are relevant for your circumstances. The sheet provides a brief outline of the study but not all information participants will need to consider when thinking about joining the study.

For more detailed information about this study, click here.

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr. Nick Manuelpillai
t: 9623 9464
e: [email protected]

Study Coordinator
Sarah Chivers
t: 9623 9465
e: [email protected]

How do I become involved in a clinical trial at the institute?

Anyone can participate in a clinical trial. A referral from a doctor is not necessary.

Contact the Clinical Trials Department directly to inquire about current research projects to determine your suitability
Phone: (03) 9623 9439
Email: [email protected]

Donate